Sanyou Bio and Guangzhou Baiyunshan Xihe Sign Strategic Agreement to Jointly Develop AI-Based Radiopharmaceuticals and Diagnostics
Combining AI-Based Target Discovery with the Nuclear Medicine Value Chain
Sanyou Biopharmaceutical and Guangzhou Baiyunshan Xihe Health Pharmaceutical have entered into a strategic collaboration to jointly develop radiopharmaceuticals and diagnostics, leveraging AI technology and radiopharmaceutical production capabilities. This partnership aims to rapidly identify highly targeted radiolabeled antibodies and integrate them into a value chain for commercialization. With the increasing global interest in radiopharmaceuticals, accelerating the discovery of innovative drug candidates has become crucial for survival. Sanyou Bio's ultra-large AI antibody library is expected to serve as a starting point for reducing the exploration period and maximizing the success rate of new drug development.
Accelerating Research and Development through Synergistic Technology Platforms
Through this partnership, Sanyou Bio will contribute its core platforms, including the 'AI-STAL (AI-Super Trillion Antibody/Molecule Libraries)' with over 11 trillion diverse molecules and 'SAI-DA (Sanyou AI-Drug Accelerator)'. These platforms will be used to screen and optimize high-performance antibodies and derivative molecules tailored for radiopharmaceutical targets. Meanwhile, Guangzhou Baiyunshan Xihe will leverage its expertise in medical radioisotope production, GMP-compliant manufacturing infrastructure, and clinical translation to drive subsequent development. This division of roles is expected to create a strong synergy, enabling the rapid transition of molecular designs from the laboratory to clinical drugs that can be administered to patients.
Implementing Theranostics Using Key Isotopes such as Gallium-68
Both companies have agreed to integrate various medical isotope technologies to realize the concept of theranostics, which combines diagnosis and treatment. Specifically, Guangzhou Baiyunshan Xihe's standardized manufacturing technology for key radioisotopes, including Gallium-68, Zirconium-89, Copper-64, and Rhenium-186, will be actively utilized. This approach involves using diagnostic isotopes to accurately identify the location of cancer, followed by the use of therapeutic isotopes to selectively target and destroy cancer cells, minimizing side effects. This is emerging as the next-generation standard for cancer treatment. This collaboration is expected to accelerate the development of domestically produced, customized precision medicine solutions incorporating advanced isotopes in China.
Securing a Leading Position in China's Rapidly Growing Radiopharmaceutical Market
China's nuclear medicine and radiopharmaceutical market is estimated to grow from approximately USD 532 million in 2024 to over USD 1.27 billion by 2035. Radiopharmaceuticals have a limited half-life, making collaboration with local partners who have established logistics chains and GMP-compliant manufacturing facilities a critical factor for market entry. By leveraging the distribution network of its parent company, Guangzhou Pharmaceutical Holdings, and the production infrastructure of Guangzhou Baiyunshan Xihe, the partnership aims to establish a strong foundation for competing with existing leaders such as China Isotope & Radiation (CIRC) in terms of market share.
This collaboration represents an efficient partnership that combines AI platform technology and GMP manufacturing capabilities to secure a leading position in China's USD 532 million radiopharmaceutical market (as of 2024). In the short term, Sanyou Bio's AI-STAL platform will be used in the candidate discovery and preclinical stages to accelerate the identification of novel target antibodies that can be combined with key isotopes such as Gallium-68. In the medium to long term, the partnership will overcome the challenges of radiopharmaceutical logistics and regulatory approvals in China by leveraging the infrastructure of Guangzhou Baiyunshan Xihe, a subsidiary of Guangzhou Pharmaceutical Holdings, thereby significantly increasing the potential for commercialization in the Chinese market. This will serve as a strategic benchmark for Asian biotech companies seeking to build an independent AI-based nuclear medicine value chain in response to the expansion of global Big Pharma companies such as Novartis and AstraZeneca in the radiopharmaceutical (RDC) market.